Bucindolol exhibits a wide range of bioactivities across various biological systems. It acts as a beta-adrenergic receptor blocker in normotensive rats, achieving 71.0% inhibition at 2 mg/kg, and demonstrates intrinsic sympathomimetic activity with 77.0 beats per minute in reserpinized rats. Additionally, it shows antihypertensive effects in spontaneously hypertensive rats with a 45.0 mmHg reduction in blood pressure following peroral administration and possesses vasodilator activity in ganglion-blocked rats, leading to a 26.0% decrease in mean arterial blood pressure at 3 mg/kg intravenously.
Bucindolol is a potent inhibitor of the enzyme Cytochrome P450 2D6 (CYP2D6), with an IC50 value of 50.0 nM after 45 minutes of incubation. It also significantly inhibits the uptake of 4-(4-(dimethylamino)styryl)-N-methylpyridinium via human OCT1 in HEK293 cells, with an IC50 of 27,200.0 nM and 84.6% inhibition at a concentration of 100 µM.
The compound shows diverse bioactivity in various other assays, including inhibition of the Menin-MLL interaction in MLL-related leukemias, GCN5L2 inhibition, delayed death inhibition of the malarial parasite plastid, and Schwann cell viability assays. Additionally, it induces DNA re-replication in SW480 colon adenocarcinoma cells, inhibits human tyrosyl-DNA phosphodiesterase 1 (TDP1), blocks viral entries, including Lassa Virus, Marburg Virus, Ebola Virus, and SARS-CoV-2, with an IC50 ranging from 16,982.44 nM to 17,000.0 nM for SARS-CoV-2. The compound also inhibits insulin secretion from INS-1E cells at different glucose concentrations, with varying potencies in the nanomolar and micromolar ranges.
Lastly, Bucindolol exhibits antiviral activity against SARS-CoV-2 in VERO-E6 cells, demonstrating an IC50 range of 16,982.44 nM to 17,000.0 nM and a CC50 value of 30,900.0 nM, indicating both its potency and certain cytotoxicity to VERO-E6 cells..
Note: Summary generated by AI. Data source: ChEMBL 